Effects of levosimendan on quality of life and emotional stress in advanced heart failure patients

Cardiovascular Drugs and Therapy

Volumn 21, Issue 4, 2007, Pages 263-268

  Parissis, John T ^a,b   Papadopoulos, Constantinos ^a   Nikolaou, Maria ^a   Bistola, Vassiliki ^a   Farmakis, Dimitrios ^a   Paraskevaidis, Ioannis ^a   Filippatos, Gerasimos ^a   Kremastinos, Dimitrios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Advanced heart failure; Calcium sensitizers; Exercise capacity; Quality of life

Indexed keywords

LEVOSIMENDAN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EMOTIONAL STRESS; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

AGED; CARDIOTONIC AGENTS; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PSYCHOMETRICS; PYRIDAZINES; QUALITY OF LIFE; QUESTIONNAIRES; STRESS, PSYCHOLOGICAL;

EID: 34548594207     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6034-2     Document Type: Article

References (26)

1. McBride BF, White MC. Levosimendan: implications for clinicians. J Clin Pharmacol 2003;43:1071-81.
2. Innes CA, Wagstaff AJ. Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs 2003;63:2651-71.
3. Kass DA, Solaro J. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006;113:305-15.
4. Parissis JT, Filippatos G, Farmakis D, Adamopoulos S, Paraskevaidis I, Kremastinos D. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother 2005;6:2741-51.
5. Jamali IN, Kersten JR, Pagel PS, Hettrick DA, Warltier DC. Intra-coronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997;85:23-9.
6. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222-7.
7. Nieminem M, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-12.
8. Follath F, Cleland JGF, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002;360:196-202.
9. Maisel AS, Krshnawamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Breathing not properly multinational study investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
10. Beck AT, Steer RA, Garbin MG. Psychometric properties of Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988;8:77-100.
11. Zung WWK, Richards CB, Short MJ. Self-rating depression scale in an outpatient clinic. Arch Gen Psychiatry 1965;13:508-15.
12. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245-55.
13. Hlatky M, Boineau R, Higginbotham M, Lee KL, Mark DB, Califf RM, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol 1989;15:651-4.
14. Packer M, Colucci WS, Fisher L. Development of a comprehensive new end-point for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study. J Card Fail 2003;9:S61.
15. Parissis J, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005;96:423-6.
16. Tachinaba H, Cheng HJ, Ukai T, Igawa A, Zhang Z-S, Little WC, et al. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 2005;288:H914-22.
17. Parissis J, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004;93:1309-12.
18. Heidenreich PA, Spertus JA, Jones PG, Weintraub WS, Rumsfeld JS, Rathore SS, et al. Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol 2006;47:752-6.
19. Havranek EP, Ware M, Lowes BD. Prevalence of depression in patients with congestive heart failure. Am J Cardiol 1999;84:348-50.
20. Joynt KE, Whellan DJ, O' Connor CM. Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. J Card Fail 2004;10:258-70.
21. Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden LH, Cuffe MS, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001;161:1849-56.
22. Adamopoulos S, Parissis J, Kremastinos D. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 2001;3:517-26.
23. Pasic J, Levy WC, Sullivan MD. Cytokines in depression and heart failure. Psychosom Med 2003;65:181-93.
24. Parissis J, Adamopoulos S, Rigas A, Kostakis G, Karatzas D, Venetsanou K, et al. Comparison of circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am J Cardiol 2004;94:1326-8.
25. Ferketich A, Ferguson JP, Binkley PF. Depressive symptoms and inflammation among heart failure patients. Am Heart J 2005;150:132-6.
26. Maytin M, Colucci W. Cardioprotection: a new paradigm in the acute management of acute heat failure syndromes. Am J Cardiol 2005;96:26G-31G.